Abstract
Connective tissue diseases are a heterogeneous group of autoimmune diseases that can affect a variety of organ systems. Lung parenchymal involvement is an important contributor to morbidity and mortality in children with connective tissue disease. Connective tissue disease-associated lung disease in children often manifests as one of several radiologic-pathologic patterns of disease, with certain patterns having a propensity to occur in association with certain connective tissue diseases. In this article, key clinical, histopathologic, and computed tomography (CT) features of typical patterns of connective tissue disease-associated lung disease in children are reviewed, with an emphasis on radiologic-pathologic correlation, to improve recognition of these patterns of lung disease at CT and to empower the pediatric radiologist to more fully contribute to the care of pediatric patients with these conditions.
Graphical abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Connective tissue diseases represent a heterogeneous group of autoimmune diseases characterized by sustained inflammation, circulating autoantibodies, and organ damage [1, 2]. Lung parenchymal disease can occur in association with connective tissue disease in children, with certain lung disease patterns tending to occur in association with certain connective tissue diseases. The radiologist can play a valuable role in identifying and characterizing connective tissue disease-associated lung disease, tracking lung disease over time, suggesting the possibility of connective tissue disease in undiagnosed patients with appropriate imaging findings, and suggesting possible alternative or superimposed processes in patients with known connective tissue disease and abnormal lung findings on imaging.
We will first briefly discuss connective tissue disease-associated lung disease generally as well as the role of the radiologist in diagnosis and management of connective tissue disease-associated lung disease. We will then describe key clinical, histopathological, and computed tomography (CT) features of lung diseases seen in children with systemic sclerosis, Sjogren syndrome, juvenile dermatomyositis, systemic lupus erythematosus, juvenile idiopathic arthritis, and mixed connective tissue disease to familiarize the pediatric radiologist with this group of disorders.
Connective tissue disease-associated lung disease
Several patterns of lung disease tend to be seen with connective tissue disease-associated lung disease including nonspecific interstitial pneumonia, organizing pneumonia, lymphoid interstitial pneumonia, diffuse alveolar damage, and a spectrum of pulmonary alveolar proteinosis and endogenous lipoid pneumonia. Because the interstitium is not the only portion of the lung involved in multiple of these pathologies, we refrain from using the often used terminology “interstitial lung disease” when describing these entities. While certain patterns of lung disease tend to occur in association with certain connective tissue diseases, more than one of these patterns can be associated with each connective tissue disease and many of the patterns can be seen with more than one connective tissue disease (Table 1). Although pediatric connective tissue disease-associated lung disease most often presents after a connective tissue disease diagnosis has already been made, it can occasionally be the presenting manifestation [3, 4].
The specifics of these connective tissue disease-associated lung disease patterns will be described below, with each pattern discussed in more detail along with a connective tissue disease that it tends to be associated with so that each pattern is ultimately discussed in this article. In general, connective tissue disease-associated lung disease tends to be bilateral and relatively symmetric. In addition, preferential involvement of the anterior subpleural aspect of both upper lobes and involvement of the lower lobes is a disease distribution seen in some connective tissue disease-associated lung disease, particularly NSIP and pulmonary alveolar proteinosis/endogenous lipoid pneumonia spectrum, that is not typical of other lung diseases. This distribution has been noted in the adult connective tissue disease-associated lung disease literature as the “anterior upper lobe sign” and “four corners sign” and should prompt the radiologist to raise suspicion of connective tissue disease-associated lung disease, even in patients without known connective tissue disease [5, 6]. Additional thoracic findings associated with connective tissue disease including pleural and/or pericardial disease, airway disease, esophageal dilation, pulmonary artery enlargement, soft tissue calcifications, and joint abnormalities may also be present [7].
Role of the radiologist
After selecting an appropriate CT protocol with which to image pediatric connective tissue disease-associated lung disease (Table 2), the radiologist can help determine prognosis and treatment at initial evaluation by determining whether connective tissue disease-associated lung disease is present in patients with known connective tissue disease, and if present, by determining the pattern and extent of disease [8,9,10]. After initial evaluation, the radiologist plays a vital role in evaluating for connective tissue disease-associated lung disease progression or response to treatment to direct therapy and further determine prognosis. In addition to identifying and characterizing connective tissue disease-associated lung disease in patients with known connective tissue disease, it is also important for the radiologist to recognize and suggest the possibility of connective tissue disease-associated lung disease in patients without known connective tissue disease, as lung disease can occasionally be the presenting manifestation [3, 4]. Finally, patients with connective tissue disease can be at increased risk for lung diseases other than connective tissue disease-associated lung disease, such as infection, edema, medication-induced pulmonary injury, aspiration, and lymphoproliferative disease. Thus, it is important for the radiologist to consider the possibility of alternative or superimposed processes in patients with connective tissue disease [1, 9, 11,12,13].
Juvenile systemic sclerosis
Juvenile systemic sclerosis is a rare heterogeneous connective tissue disorder characterized by vasculopathy, inflammation, and fibrosis of the skin and internal organs in patients younger than 16 years of age [14, 15]. The mean age of disease onset is 6–11 years old, with juvenile systemic sclerosis being very uncommon before the age of 5. Similar to adult systemic sclerosis, the pediatric disease is more common in females. Lung involvement is common, with a reported prevalence of 20–90%. Lung involvement, cardiac involvement, and pulmonary hypertension represent the leading causes of morbidity and mortality in patients with systemic sclerosis [15,16,17,18,19].
The most common histologic and CT pattern seen with systemic sclerosis-associated lung disease is nonspecific interstitial pneumonia (NSIP), which is highly associated with underlying connective tissue disease, most commonly systemic sclerosis [18, 20,21,22]. Additional thoracic imaging findings seen in the setting of juvenile systemic sclerosis include esophageal dilation with layering fluid, features of aspiration, pleural thickening or effusion, and features of pulmonary hypertension [18, 23].
Nonspecific interstitial pneumonia
NSIP is histopathologically characterized by diffuse, varying amounts of interstitial inflammation and fibrosis with a temporally uniform appearance [24]. On one end of the spectrum, cellular NSIP is typified by diffuse chronic interstitial inflammation with absent or minimal fibrosis. While on the other end of the spectrum, fibrotic NSIP is characterized by diffuse, temporally uniform interstitial fibrosis with mild to moderate associated chronic inflammation. Both cellular and fibrotic NSIP lack substantial architectural distortion manifested as honeycomb change which, along with the temporal uniformity of lung injury and lack of conspicuous fibroblastic foci, differentiates NSIP from the temporally and spatially heterogeneous fibrosing entity, usual interstitial pneumonia [25,26,27] (Fig. 1).
The hallmark features of NSIP on CT include ground-glass opacity, accounted for by volume averaging of inflammation and/or fine fibrosis in the alveolar septa below the resolution of CT and air in the airspaces, as well as reticular opacities and traction bronchiectasis/bronchiolectasis that reflect areas of fibrosis [21]. The imaging findings tend to be lower lobe predominant, with a subpleural, peribronchovascular, or diffuse axial distribution. Subpleural anterior upper lobe involvement is also often seen in the setting of connective tissue disease-associated NSIP [6, 7] (Fig. 2). Subpleural sparing is not always present, but when seen is particularly suggestive of an NSIP pattern [10].
Sjogren syndrome
Sjogren syndrome is a slowly progressive systemic autoimmune disease that primarily affects the exocrine glands, although other organs can also be affected [28, 29]. While Sjogren syndrome has been described as the second most common autoimmune connective tissue disease in adults, it is rarely diagnosed in the pediatric population, potentially due to under diagnosis [30,31,32,33,34]. In the pediatric population the mean age of onset is 10 years of age, and, similar to adults, there is a female preponderance [31, 32]. Unlike adults with Sjogren syndrome, children with Sjogren syndrome present more commonly with recurrent parotitis than sicca complex symptoms [31, 35]. Although extraglandular manifestations of Sjogren syndrome are common in pediatric patients with Sjogren syndrome, pulmonary involvement is extremely rare and may manifest as bronchial/bronchiolar and/or lung parenchymal abnormalities [33, 36,37,38].
NSIP is the most common pattern of lung disease seen in patients with Sjogren syndrome. However, lymphoid interstitial pneumonia (LIP) is also strongly associated with Sjogren syndrome and is most commonly seen in association with Sjogren syndrome as compared to other connective tissue diseases [28]. Although lung disease associated with Sjogren syndrome is extremely rare in children, both SS-associated NSIP and LIP have been reported in children [34, 37].
Lymphoid interstitial pneumonia
Histologically, LIP is characterized by a diffuse densely cellular interstitial infiltrate consisting mainly of polyclonal lymphocytes and plasma cells that widen the alveolar septa resulting in distortion of alveolar spaces [39,40,41,42] (Fig. 3). Lymphoid interstitial pneumonia is considered to be an entity in a spectrum of pulmonary lymphoproliferative disorders that includes follicular bronchiolitis. Accordingly, peribronchial and peribronchiolar lymphoid follicles with reactive germinal centers are often present along with the diffuse dense lymphocytic interstitial infiltrate and lymphoid follicles expanding alveolar septa that typify LIP [40, 43,44,45].
Similar to NSIP, the combination of inflammation expanding the alveolar septa and air within the alveolar spaces in LIP is below the resolution of CT, thus resulting in ground-glass opacity, the major finding of LIP on CT. Additional CT findings of LIP include lower lung predominant peribronchovascular and subpleural cysts that may relate to partial bronchiolar obstruction by peribronchiolar lymphocytic aggregates resulting in post-obstructive bronchiolar ectasia or overinflation. Interlobular septal and peribronchovascular thickening may also be present reflecting the propensity of the lymphocytic infiltrate to be most pronounced in the perilymphatic interstitium. Ill-defined centrilobular nodules are also described, corresponding to sites of more pronounced peribronchiolar lymphocytic infiltration [39, 41, 46,47,48] (Fig. 4).
Juvenile dermatomyositis
Juvenile dermatomyositis is a systemic autoimmune vasculitis characterized by inflammatory myopathy and skin rashes. Although rare, juvenile dermatomyositis is the most common idiopathic inflammatory myopathy of childhood and presents as multiple subtypes and clinical courses [49,50,51,52]. There is a female preponderance of disease, and the average age of onset is 7 years [12, 53,54,55]. While cutaneous and muscular involvement is required for diagnosis, circulating autoantibodies may also result in lung disease. Indeed, restrictive lung disease is a rare but well-known complication of juvenile dermatomyositis, and assessment for lung disease is of particular importance given the significant associated morbidity and mortality [12, 52, 53, 56,57,58].
NSIP, organizing pneumonia (OP), and combined NSIP/OP features are the most common lung disease pathologic patterns seen in patients with dermatomyositis [12, 39, 56, 59]. Similar to NSIP, OP can be seen in the setting of numerous connective tissue disorders, but among the connective tissue diseases, OP is most commonly seen in association with dermatomyositis [28]. Diffuse alveolar damage (DAD) uncommonly occurs in association with juvenile dermatomyositis but is notable for its high mortality rate [60]. Aspiration resulting from pharyngeal-esophageal dysmotility and hypoventilation due to respiratory muscle dysfunction may also account for respiratory manifestations in patients with juvenile dermatomyositis [12].
Organizing pneumonia
The hallmark histopathologic finding of OP is polypoid fibroinflammatory tissue filling distal bronchioles, alveolar ducts, and peribronchiolar alveoli with intact alveolar septa involved by mild interstitial inflammation [61,62,63] (Fig. 5).
OP usually appears on CT as peribronchovascular and/or peripheral areas of consolidation with or without ground-glass opacity. The consolidation seen at imaging corresponds to dense plugging of small airways and alveolar spaces with fibroinflammatory tissue combined with alveolar septal thickening. The ground-glass opacity corresponds to alveolar septal thickening, intraluminal cellular debris, and lesser amounts of intraluminal fibroinflammatory tissue [61, 64,65,66,67,68,69,70,71]. Additional CT findings include perilobular opacities seen as subpleural predominant ill-defined curvilinear or polygonal opacities surrounded by aerated lung, and the “reversed halo”/“atoll” sign in which crescentic or ring-shaped consolidation surrounds areas of ground-glass opacity [65, 70,71,72] (Fig. 6). Single or multiple ill-defined nodular opacities can also be seen in the setting of OP, often in a peribronchial/peribronchiolar distribution with internal air bronchograms, but other findings of OP are usually also present [61, 73, 74]. Over time, CT findings of OP can completely resolve, although findings of fibrosis including reticulation, ground-glass opacity (reflecting fine fibrosis), parenchymal bands, architectural distortion, and/or traction bronchiectasis/bronchiolectasis, sometimes in an NSIP pattern, may remain at follow-up [68, 69, 73].
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a severe, chronic, systemic autoimmune disease that impacts multiple organ systems [75]. Approximately 20% of cases are diagnosed during childhood, although very rarely before 5 years of age [76]. While adult-onset SLE is seen predominantly in females at a 13:1 ratio, significantly more males are diagnosed in the pediatric age group with an overall female-to-male ratio of 6:1 [76]. Typically, childhood-onset SLE has a more severe clinical phenotype than adult-onset SLE [75, 76]. Thoracic findings of SLE are common and include pleuritis and/or pericarditis with or without effusion, acute and chronic lung disease, shrinking lung syndrome, pulmonary arterial hypertension (PAH), and pulmonary embolism [77,78,79].
Among the acute lung diseases seen in the setting of SLE are “acute lupus pneumonitis,” which manifests histopathologically as DAD, and diffuse alveolar hemorrhage (DAH). Both of these severe pulmonary manifestations of SLE are rare but, importantly, are associated with a high mortality rate [77, 80, 81]. Chronic lung disease is uncommon in the setting of SLE, with NSIP being the most common pattern observed [77].
Diffuse alveolar damage
The histopathologic features of DAD are dependent upon the timing of tissue sampling after lung injury. In the first week or acute phase of lung injury, intra-alveolar and alveolar wall edema as well as hyaline membranes composed of cellular debris, plasma proteins, and surfactant predominate. Thrombi may also be present in small pulmonary arteries and capillaries. Starting in the second week or organizing phase of lung injury, fibroblast and alveolar epithelial type II pneumocyte hyperplasia predominates and may result in structural remodeling and fibrosis [82,83,84,85] (Fig. 7).
The major CT finding in the acute DAD phase is patchy, but typically extensive, geographic ground-glass opacity, often accompanied by interlobular septal thickening and areas of consolidation. These CT findings correspond to the airspace filling by cellular debris and exudative fluid as well as interstitial edema seen in the histopathology [74, 86] (Fig. 8). Dependent atelectasis is also commonly seen in the acute DAD stage [87]. In the organizing DAD phase, more widespread lung involvement will often be seen, with a greater degree of dependent-predominant consolidation and volume loss as well as traction bronchiectasis/bronchiolectasis [74, 88, 89]. Although the imaging features may ultimately resolve over time, fibrosis frequently remains that appears on CT as reticulation, parenchymal bands, architectural distortion, and traction bronchiectasis/bronchiolectasis [86, 90,91,92].
Juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is not a single entity, but a term encompassing all forms of arthritis of unknown origin that begin before a patient is 16 years of age and persist for more than 6 weeks [93, 94]. Systemic JIA is a category of JIA that tends to occur in young children and is characterized by arthritis and prominent systemic/extraarticular features including daily spiking fever, evanescent rash, generalized lymph node enlargement, hepatomegaly, splenomegaly, and/or serositis [94,95,96,97]. Although pleuritis/pleural effusion and pericarditis/pericardial effusion are the most common thoracic manifestations of systemic JIA, in the past decade there has been increasing recognition of a lung disease with high mortality in systemic JIA patients. Patients with systemic JIA that develop the lung disease tend to be young at systemic JIA onset (i.e., less than 3–5 years of age), and have a history of macrophage activation syndrome, reaction to cytokine-targeted biologics (particularly tocilizumab), and digital clubbing [8, 98].
Pulmonary alveolar proteinosis and endogenous lipoid pneumonia
The histopathology of systemic JIA-associated lung disease lies on a spectrum of combined features of pulmonary alveolar proteinosis and endogenous lipoid pneumonia, a distinct pattern in rheumatic disease [8, 98]. The pulmonary alveolar proteinosis end of the spectrum is characterized by predominant distal airway and alveolar space filling with granular proteinaceous material with variable numbers of alveolar macrophages with vacuolated foamy cytoplasm and cholesterol clefts. The endogenous lipoid pneumonia end of the spectrum is typified by more abundant macrophages and multinucleated giant cells containing vacuoles both within airspaces and the interstitium. Cholesterol clefts are often more prominent and associated with a fibroinflammatory response (Fig. 9). Vasculopathy can also be seen in systemic JIA-associated lung disease including arterial hypertensive changes with arterial wall thickening.
On CT, systemic JIA-associated lung disease typically manifests as ground-glass opacity when at least partial aeration of airspaces remains in areas of lung involvement, consolidation when there is no remaining air in the airspaces, and/or interlobular septal thickening. Sometimes areas of ground-glass opacity have superimposed interlobular septal thickening and intralobular lines in a crazy paving pattern. Lung findings are typically seen in a subpleural and/or peribronchovascular distribution, although they can be diffuse. When subpleural involvement is seen it tends to involve the anterior upper lobes and peripheral lower lobes (Figs. 10 and 11). Subpleural predominant cysts can also be seen in patients with advanced disease [8, 99] (Fig. 12).
Mixed connective tissue disease
Mixed connective tissue disease (MCTD) is characterized by a combination of features of systemic sclerosis, systemic lupus erythematosus, and dermatomyositis associated with a high titer of anti-U1 ribonucleoprotein antibodies [100, 101]. Among all MCTD cases, 23% begin in childhood [102]. MCTD is one of the least frequent rheumatologic diseases seen in the pediatric population, with a median age of onset of 11 years and a three times increased incidence in girls as compared to boys [103]. Typical clinical manifestations include arthritis, Raynaud phenomenon, swollen fingers and hands, myositis, esophageal dysmotility, fever, and skin changes that are seen with systemic sclerosis, SLE, and/or juvenile dermatomyositis [23, 101, 104, 105].
Thoracic manifestations include a combination of features seen with systemic sclerosis, SLE, and juvenile dermatomyositis. Lung disease is common and typically manifests as NSIP, OP, or overlapping NSIP/OP patterns of disease [1, 10, 104, 106,107,108,109,110,111] (Fig. 13). Pleuritis and/or pericarditis in the presence or absence of effusions can also be seen [104, 112, 113]. Accompanying pulmonary hypertension is rare in children, but is a serious complication associated with increased mortality [101, 102, 104, 114]. Pulmonary arterial hypertension in the setting of MCTD pathologically manifests as pulmonary arterial intimal proliferation and medial hyperplasia that is accompanied by little or no interstitial fibrosis in the surrounding lung parenchyma [1, 102].
Conclusion
Connective tissue disease-associated lung disease typically manifests as one of several patterns of lung disease, with certain lung disease patterns tending to occur in association with certain connective tissue diseases (Table 3). Knowledge of these lung disease patterns and the connective tissue diseases they are associated with can help the radiologist identify and better characterize connective tissue disease-associated lung disease. We conclude this article with a few key take-home points regarding connective tissue disease-associated lung disease in children:
-
Connective tissue disease-associated lung disease should be considered if any of the described CT patterns of lung disease are observed, even in patients without known connective tissue disease, with suspicion heightened if bilateral subpleural anterior upper lobe involvement is present or there are other thoracic manifestations associated with connective tissue disease.
-
NSIP and organizing pneumonia can be seen in association with any of the connective tissue diseases.
-
LIP is most commonly associated with Sjogren syndrome.
-
A spectrum of pulmonary alveolar proteinosis and endogenous lipoid pneumonia is unique to systemic JIA among the connective tissue diseases.
-
Diffuse alveolar damage can be seen in juvenile dermatomyositis and SLE and is associated with a high mortality rate.
-
Alternative or superimposed processes such as infection, edema, medication-induced pulmonary injury, aspiration, and lymphoproliferative disease should be considered in addition to connective tissue disease-associated lung disease in patients with connective tissue disease.
Data availability
Not applicable.
Code availability
Not applicable.
References
Ahuja J, Arora D, Kanne JP et al (2016) Imaging of Pulmonary manifestations of connective tissue diseases. Radiol Clin North Am 54:1015–1031
Gaubitz M (2006) Epidemiology of connective tissue disorders. Rheumatology (Oxford) 45(Suppl 3):iii3–4
Vece TJ, Fan LL (2010) Interstitial lung disease in children older Than 2 years. Pediatr Allergy Immunol Pulmonol 23:33–41
Ciftci E, Yalcinkaya F, Ince E et al (2004) Pulmonary involvement in childhood-onset systemic lupus erythematosus: a report of five cases. Rheumatology (Oxford) 43:587–591
Chung JH, Cox CW, Montner SM et al (2018) CT features of the Usual interstitial pneumonia pattern: differentiating connective tissue Disease-Associated interstitial lung Disease from Idiopathic Pulmonary Fibrosis. AJR Am J Roentgenol 210:307–313
Walkoff L, White DB, Chung JH et al (2018) The four corners sign: a specific imaging feature in differentiating systemic sclerosis-related interstitial lung Disease from Idiopathic Pulmonary Fibrosis. J Thorac Imaging 33:197–203
Henry TS, Little BP, Veeraraghavan S et al (2016) The spectrum of interstitial lung disease in connective tissue disease. J Thorac Imaging 31:65–77
Saper VE, Chen G, Deutsch GH et al (2019) Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 78:1722–1731
Valeur NS, Stevens AM, Ferguson MR et al (2015) Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol 204:408–422
Elicker BM, Kallianos KG, Henry TS (2019) Imaging of the thoracic manifestations of connective tissue disease. Clin Chest Med 40:655–666
Sridhar S, Kanne JP, Henry TS et al (2022) Medication-induced Pulmonary Injury: a scenario- and pattern-based Approach to a Perplexing Problem. Radiographics 42:38–55
Pouessel G, Deschildre A, Le Bourgeois M et al (2013) The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol 48:1016–1025
Schapiro AH, Wikenheiser-Brokamp KA, Wermers JD et al (2022) Pulmonary lymphoproliferative disorders in children: a practical review. Pediatr Radiol 52:1224–1233
van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755
Martini G, Foeldvari I, Russo R et al (2006) Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 54:3971–3978
Panigada S, Ravelli A, Silvestri M et al (2009) HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr Pulmonol 44:1226–1234
Seely JM, Jones LT, Wallace C et al (1998) Systemic sclerosis: using high-resolution CT to detect lung disease in children. AJR Am J Roentgenol 170:691–697
Perelas A, Arrossi AV, Highland KB (2019) Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med 40:501–518
Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944
Desai SR, Veeraraghavan S, Hansell DM et al (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232:560–567
Kligerman SJ, Groshong S, Brown KK, Lynch DA (2009) Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. Radiographics 29:73–87
Arrossi AV (2019) Pulmonary Pathology in Rheumatic Disease. Clin Chest Med 40:667–677
Navallas M, Inarejos Clemente EJ, Iglesias E et al (2019) Connective tissue disorders in Childhood: are they all the same? Radiographics 39:229–250
Travis WD, Costabel U, Hansell DM et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748
Katzenstein AL, Fiorelli RF (1994) Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 18:136–147
Travis WD, Matsui K, Moss J, Ferrans VJ (2000) Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 24:19–33
Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205:e18–e47
Natalini JG, Johr C, Kreider M (2019) Pulmonary involvement in Sjogren Syndrome. Clin Chest Med 40:531–544
Ramos-Casals M, Font J (2005) Primary Sjogren’s syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) 44:1354–1367
Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15–25
Cimaz R, Casadei A, Rose C et al (2003) Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr 162:661–665
Civilibal M, Canpolat N, Yurt A et al (2007) A child with primary Sjogren syndrome and a review of the literature. Clin Pediatr (Phila) 46:738–742
Hammenfors DS, Valim V, Bica B et al (2020) Juvenile Sjogren’s syndrome: clinical characteristics with focus on salivary gland Ultrasonography. Arthritis Care Res (Hoboken) 72:78–87
Houghton K, Malleson P, Cabral D et al (2005) Primary Sjogren’s syndrome in children and adolescents: are proposed diagnostic criteria applicable? J Rheumatol 32:2225–2232
Yokogawa N, Lieberman SM, Sherry DD, Vivino FB (2016) Features of childhood Sjogren’s syndrome in comparison to adult Sjogren’s syndrome: considerations in establishing child-specific diagnostic criteria. Clin Exp Rheumatol 34:343–351
Anaya JM, Ogawa N, Talal N (1995) Sjogren’s syndrome in childhood. J Rheumatol 22:1152–1158
Bartholomeo A, Aujla S, Eklund M et al (2022) Pulmonary manifestations of childhood-onset primary Sjogren’s syndrome (SS) masquerading as reactive airways disease in a male patient and review of interstitial lung disease associated with SS. Pediatr Rheumatol Online J 20:101
Tomiita M, Saito K, Kohno Y et al (1997) The clinical features of Sjogren’s syndrome in Japanese children. Acta Paediatr Jpn 39:268–272
Desai S (2021) Webb, Muller and Naidich’s high-resolution CT of the lung. Wolters Kluwer Health, Philadelphia
Swigris JJ, Berry GJ, Raffin TA, Kuschner WG (2002) Lymphoid interstitial pneumonia: a narrative review. Chest 122:2150–2164
Kradin RL, Mark EJ (1983) Benign lymphoid disorders of the lung, with a theory regarding their development. Hum Pathol 14:857–867
Panchabhai TS, Farver C, Highland KB (2016) Lymphocytic interstitial pneumonia. Clin Chest Med 37:463–474
Prenzel F, Harfst J, Schwerk N et al (2020) Lymphocytic interstitial pneumonia and follicular bronchiolitis in children: a registry-based case series. Pediatr Pulmonol 55:909–917
Guinee DG Jr (2010) Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities. Arch Pathol Lab Med 134:691–701
Nicholson AG (2001) Lymphocytic interstitial pneumonia and other lymphoproliferative disorders in the lung. Semin Respir Crit Care Med 22:409–422
Johkoh T, Muller NL, Pickford HA et al (1999) Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients. Radiology 212:567–572
Ichikawa Y, Kinoshita M, Koga T et al (1994) Lung cyst formation in lymphocytic interstitial pneumonia: CT features. J Comput Assist Tomogr 18:745–748
Desai SR, Nicholson AG, Stewart S et al (1997) Benign pulmonary lymphocytic infiltration and amyloidosis: computed tomographic and pathologic features in three cases. J Thorac Imaging 12:215–220
Kobayashi I, Okura Y, Yamada M et al (2011) Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 158:675–677
Li D, Tansley SL (2019) Juvenile dermatomyositis-clinical phenotypes. Curr Rheumatol Rep 21:74
Stringer E, Singh-Grewal D, Feldman BM (2008) Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 58:3585–3592
Bellutti Enders F, Bader-Meunier B, Baildam E et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329–340
Batthish M, Feldman BM (2011) Juvenile dermatomyositis. Curr Rheumatol Rep 13:216–224
Cassidy JT (2011) Textbook of pediatric rheumatology. Saunders, Philadelphia
Kobayashi N, Takezaki S, Kobayashi I et al (2015) Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 54:784–791
Kobayashi I, Yamada M, Takahashi Y et al (2003) Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 42:371–374
Trapani S, Camiciottoli G, Vierucci A et al (2001) Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford) 40:216–220
Mathiesen PR, Buchvald F, Nielsen KG et al (2014) Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients. Rheumatology (Oxford) 53:644–649
Arakawa H, Yamada H, Kurihara Y et al (2003) Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 123:1096–1103
Matsuki Y, Yamashita H, Takahashi Y et al (2012) Diffuse alveolar damage in patients with dermatomyositis: a six-case series. Mod Rheumatol 22:243–248
Myers JL, Katzenstein AL (1988) Ultrastructural evidence of alveolar epithelial injury in idiopathic bronchiolitis obliterans-organizing pneumonia. Am J Pathol 132:102–109
King TE Jr., Lee JS (2022) Cryptogenic Organizing Pneumonia. N Engl J Med 386:1058–1069
Peyrol S, Cordier JF, Grimaud JA (1990) Intra-alveolar fibrosis of idiopathic bronchiolitis obliterans-organizing pneumonia. Cell-matrix patterns. Am J Pathol 137:155–170
Nishimura K, Itoh H (1992) High-resolution computed tomographic features of bronchiolitis obliterans organizing pneumonia. Chest 102:26S–31S
Voloudaki AE, Bouros DE, Froudarakis ME et al (1996) Crescentic and ring-shaped opacities. CT features in two cases of bronchiolitis obliterans organizing pneumonia (BOOP). Acta Radiol 37:889–892
Muller NL, Staples CA, Miller RR (1990) Bronchiolitis obliterans organizing pneumonia: CT features in 14 patients. AJR Am J Roentgenol 154:983–987
Lee KS, Kullnig P, Hartman TE, Muller NL (1994) Cryptogenic organizing pneumonia: CT findings in 43 patients. AJR Am J Roentgenol 162:543–546
Lee JW, Lee KS, Lee HY et al (2010) Cryptogenic organizing pneumonia: serial high-resolution CT findings in 22 patients. AJR Am J Roentgenol 195:916–922
Chung MP, Nam BD, Lee KS et al (2018) Serial chest CT in cryptogenic organizing pneumonia: evolutional changes and prognostic determinants. Respirology 23:325–330
Kim SJ, Lee KS, Ryu YH et al (2003) Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. AJR Am J Roentgenol 180:1251–1254
Ujita M, Renzoni EA, Veeraraghavan S et al (2004) Organizing pneumonia: perilobular pattern at thin-section CT. Radiology 232:757–761
Zompatori M, Poletti V, Battista G, Diegoli M (1999) Bronchiolitis obliterans with organizing pneumonia (BOOP), presenting as a ring-shaped opacity at HRCT (the atoll sign). A case report. Radiol Med 97:308–310
Akira M, Yamamoto S, Sakatani M (1998) Bronchiolitis obliterans organizing pneumonia manifesting as multiple large nodules or masses. AJR Am J Roentgenol 170:291–295
Kligerman SJ, Franks TJ, Galvin JR (2013) From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics 33:1951–1975
Groot N, de Graeff N, Avcin T et al (2017) European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 76:1788–1796
Ambrose N, Morgan TA, Galloway J et al (2016) Differences in disease phenotype and severity in SLE across age groups. Lupus 25:1542–1550
Shin JI, Lee KH, Park S et al (2022) Systemic lupus erythematosus and lung involvement: a Comprehensive Review. J Clin Med 11
Amarnani R, Yeoh SA, Denneny EK, Wincup C (2020) Lupus and the lungs: the Assessment and Management of Pulmonary manifestations of systemic Lupus Erythematosus. Front Med (Lausanne) 7:610257
Lalani TA, Kanne JP, Hatfield GA, Chen P (2004) Imaging findings in systemic lupus erythematosus. Radiographics 24:1069–1086
Kim JS, Lee KS, Koh EM et al (2000) Thoracic involvement of systemic lupus erythematosus: clinical, pathologic, and radiologic findings. J Comput Assist Tomogr 24:9–18
Blay G, Rodrigues JC, Ferreira JCO et al (2018) Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: a severe disease flare with serious outcome. Adv Rheumatol 58:39
Fukuda Y, Ishizaki M, Masuda Y et al (1987) The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 126:171–182
Thille AW, Esteban A, Fernandez-Segoviano P et al (2013) Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med 1:395–401
Burkhardt A (1989) Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 140:513–524
Katzenstein AL (1985) Pathogenesis of fibrosis in interstitial pneumonia: an electron microscopic study. Hum Pathol 16:1015–1024
Ferguson EC, Berkowitz EA (2012) Lung CT: part 2, the interstitial pneumonias–clinical, histologic, and CT manifestations. AJR Am J Roentgenol 199:W464–476
Marquis KM, Hammer MM, Steinbrecher K et al (2023) CT Approach to Lung Injury. Radiographics 43:e220176
Rouby JJ, Puybasset L, Nieszkowska A, Lu Q (2003) Acute respiratory distress syndrome: lessons from computed tomography of the whole lung. Crit Care Med 31:S285–295
Ichikado K, Suga M, Gushima Y et al (2000) Hyperoxia-induced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings. Radiology 216:531–538
Desai SR, Wells AU, Rubens MB et al (1999) Acute respiratory distress syndrome: CT abnormalities at long-term follow-up. Radiology 210:29–35
Wilcox ME, Patsios D, Murphy G et al (2013) Radiologic outcomes at 5 years after severe ARDS. Chest 143:920–926
Nobauer-Huhmann IM, Eibenberger K, Schaefer-Prokop C et al (2001) Changes in lung parenchyma after acute respiratory distress syndrome (ARDS): assessment with high-resolution computed tomography. Eur Radiol 11:2436–2443
Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369:767–778
Prakken B, Albani S, Martini A (2011) Juvenile idiopathic arthritis. Lancet 377:2138–2149
Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392
Woo P (2006) Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2:28–34
Martini A, Lovell DJ (2010) Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis 69:1260–1263
Schulert GS, Yasin S, Carey B et al (2019) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: characterization and risk factors. Arthritis Rheumatol 71:1943–1954
Vega-Fernandez P, Ting TV, Mar DA et al (2023) Lung Ultrasound in Children with systemic Juvenile Idiopathic Arthritis-Associated interstitial lung disease. Arthritis Care Res (Hoboken) 75:983–988
Sharp GC, Irvin WS, Tan EM et al (1972) Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159
Berard RA, Laxer RM (2016) Pediatric mixed connective tissue disease. Curr Rheumatol Rep 18:28
Burdt MA, Hoffman RW, Deutscher SL et al (1999) Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42:899–909
Bowyer S, Roettcher P (1996) Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 23:1968–1974
Michels H (1997) Course of mixed connective tissue disease in children. Ann Med 29:359–364
Lundberg I, Hedfors E (1991) Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 18:1511–1519
Kozuka T, Johkoh T, Honda O et al (2001) Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging 16:94–98
Yamanaka Y, Baba T, Hagiwara E et al (2018) Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis/dermatomyositis. Eur J Radiol 107:26–32
Gunnarsson R, Aalokken TM, Molberg O et al (2012) Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 71:1966–1972
Gunnarsson R, El-Hage F, Aalokken TM et al (2016) Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55:103–108
Bodolay E, Szekanecz Z, Devenyi K et al (2005) Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 44:656–661
Tiddens HA, van der Net JJ, de Graeff-Meeder ER et al (1993) Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr 122:191–197
Garcia-Pena P, Boixadera H, Barber I et al (2011) Thoracic findings of systemic diseases at high-resolution CT in children. Radiographics 31:465–482
Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM (2009) Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 33:882–896
Hajas A, Szodoray P, Nakken B et al (2013) Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol 40:1134–1142
Author information
Authors and Affiliations
Contributions
A.H.S. conceived the manuscript concept and supervised manuscript construction. A.H.S, C.E.M., K.A.W., and A.A.T. all contributed substantially to writing, reviewing, and approving the final manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Schapiro, A.H., Morin, C.E., Wikenheiser-Brokamp, K.A. et al. Connective tissue disease-associated lung disease in children. Pediatr Radiol 54, 1059–1074 (2024). https://doi.org/10.1007/s00247-024-05962-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-024-05962-0